Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | MIR22HG | Human | (1->4)-beta-D-glucan | multiple interactions | ISO | Mir22hg (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of MIR22HG mRNA | CTD | PMID:36331819 | MIR22HG | Human | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of MIR22HG mRNA | CTD | PMID:31614463 | MIR22HG | Human | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | EXP | | 6480464 | Dihydrotestosterone results in increased expression of MIR22HG mRNA | CTD | PMID:29581250 | MIR22HG | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MIR22HG mRNA | CTD | PMID:20106945 and PMID:21632981 | MIR22HG | Human | acetaldehyde | decreases expression | EXP | | 6480464 | Acetaldehyde results in decreased expression of MIR22HG mRNA | CTD | PMID:23416264 | MIR22HG | Human | acrolein | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of MIR22HG mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of MIR22HG mRNA | CTD | PMID:32699268 | MIR22HG | Human | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of MIR22HG mRNA | CTD | PMID:32763439 | MIR22HG | Human | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of MIR22HG mRNA | CTD | PMID:21641981 and PMID:27153756 | MIR22HG | Human | all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of MIR22HG mRNA | CTD | PMID:16249480 and PMID:21934132 | MIR22HG | Human | alpha-pinene | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of MIR22HG mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in decreased expression of MIR22HG mRNA | CTD | PMID:32699268 | MIR22HG | Human | ampicillin | decreases expression | EXP | | 6480464 | Ampicillin results in decreased expression of MIR22HG mRNA | CTD | PMID:21632981 | MIR22HG | Human | aristolochic acid A | increases expression | EXP | | 6480464 | aristolochic acid I results in increased expression of MIR22HG mRNA | CTD | PMID:33212167 | MIR22HG | Human | arsane | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of MIR22HG mRNA | CTD | PMID:32525701 | MIR22HG | Human | arsenic atom | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of MIR22HG mRNA | CTD | PMID:32525701 | MIR22HG | Human | benzene | increases expression | EXP | | 6480464 | Benzene results in increased expression of MIR22HG mRNA | CTD | PMID:15929907 and PMID:19162166 | MIR22HG | Human | benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of MIR22HG mRNA | CTD | PMID:20106945 more ... | MIR22HG | Human | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of MIR22HG mRNA | CTD | PMID:30903817 | MIR22HG | Human | bisphenol A | increases expression | ISO | Mir22hg (Mus musculus) | 6480464 | bisphenol A results in increased expression of MIR22HG mRNA | CTD | PMID:34585602 | MIR22HG | Human | bisphenol A | decreases expression | ISO | Mir22hg (Mus musculus) | 6480464 | bisphenol A results in decreased expression of MIR22HG mRNA | CTD | PMID:25594700 and PMID:32156529 | MIR22HG | Human | calcitriol | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of MIR22HG mRNA | CTD | PMID:21592394 | MIR22HG | Human | calcitriol | increases expression | EXP | | 6480464 | Calcitriol results in increased expression of MIR22HG mRNA | CTD | PMID:21592394 | MIR22HG | Human | carbon nanotube | increases expression | ISO | Mir22hg (Mus musculus) | 6480464 | Nanotubes and Carbon analog results in increased expression of MIR22HG mRNA | CTD | PMID:25620056 | MIR22HG | Human | carbon nanotube | decreases expression | ISO | Mir22hg (Mus musculus) | 6480464 | Nanotubes and Carbon results in decreased expression of MIR22HG mRNA | CTD | PMID:25554681 | MIR22HG | Human | chlordecone | increases expression | ISO | Mir22hg (Mus musculus) | 6480464 | Chlordecone results in increased expression of MIR22HG mRNA | CTD | PMID:33711761 | MIR22HG | Human | cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of MIR22HG mRNA | CTD | PMID:19561079 and PMID:21603599 | MIR22HG | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of MIR22HG mRNA | CTD | PMID:27392435 | MIR22HG | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of MIR22HG mRNA and Cisplatin results in increased stability of and results in increased expression of MIR22HG mRNA | CTD | PMID:24036268 and PMID:27392435 | MIR22HG | Human | cobalt dichloride | increases expression | EXP | | 6480464 | cobaltous chloride results in increased expression of MIR22HG mRNA | CTD | PMID:19376846 and PMID:22941251 | MIR22HG | Human | copper atom | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of MIR22HG mRNA | CTD | PMID:20971185 | MIR22HG | Human | copper(0) | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of MIR22HG mRNA | CTD | PMID:20971185 | MIR22HG | Human | copper(II) sulfate | increases expression | EXP | | 6480464 | Copper Sulfate results in increased expression of MIR22HG mRNA | CTD | PMID:19549813 | MIR22HG | Human | crocidolite asbestos | increases expression | EXP | | 6480464 | Asbestos and Crocidolite results in increased expression of MIR22HG mRNA | CTD | PMID:18687144 | MIR22HG | Human | curcumin | increases expression | EXP | | 6480464 | Curcumin results in increased expression of MIR22HG mRNA | CTD | PMID:17999991 | MIR22HG | Human | cycloheximide | multiple interactions | EXP | | 6480464 | Cycloheximide results in increased stability of and results in increased expression of MIR22HG mRNA | CTD | PMID:24036268 | MIR22HG | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of MIR22HG mRNA | CTD | PMID:20106945 and PMID:21632981 | MIR22HG | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of MIR22HG mRNA | CTD | PMID:22147139 | MIR22HG | Human | cylindrospermopsin | increases expression | EXP | | 6480464 | cylindrospermopsin results in increased expression of MIR22HG mRNA | CTD | PMID:24921660 | MIR22HG | Human | cytarabine | decreases expression | EXP | | 6480464 | Cytarabine results in decreased expression of MIR22HG mRNA | CTD | PMID:21198554 | MIR22HG | Human | diazinon | increases methylation | EXP | | 6480464 | Diazinon results in increased methylation of MIR22HG gene | CTD | PMID:22964155 | MIR22HG | Human | dioxygen | multiple interactions | ISO | Mir22hg (Mus musculus) | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of MIR22HG mRNA | CTD | PMID:30529165 | MIR22HG | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | MIR22HG | Human | formaldehyde | increases expression | EXP | | 6480464 | Formaldehyde results in increased expression of MIR22HG mRNA | CTD | PMID:20655997 | MIR22HG | Human | hydrogen peroxide | affects expression | EXP | | 6480464 | Hydrogen Peroxide affects the expression of MIR22HG mRNA | CTD | PMID:20044591 | MIR22HG | Human | leflunomide | decreases expression | EXP | | 6480464 | leflunomide results in decreased expression of MIR22HG mRNA | CTD | PMID:28988120 | MIR22HG | Human | mercury dibromide | increases expression | EXP | | 6480464 | mercuric bromide results in increased expression of MIR22HG mRNA | CTD | PMID:26272509 | MIR22HG | Human | mercury dibromide | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA | CTD | PMID:27188386 | MIR22HG | Human | methylmercury chloride | increases expression | EXP | | 6480464 | methylmercuric chloride results in increased expression of MIR22HG mRNA | CTD | PMID:28001369 | MIR22HG | Human | nickel atom | increases expression | EXP | | 6480464 | Nickel results in increased expression of MIR22HG mRNA | CTD | PMID:25583101 | MIR22HG | Human | ozone | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of MIR22HG mRNA more ... | CTD | PMID:32699268 | MIR22HG | Human | p-chloromercuribenzoic acid | increases expression | EXP | | 6480464 | p-Chloromercuribenzoic Acid results in increased expression of MIR22HG mRNA | CTD | PMID:26272509 | MIR22HG | Human | p-chloromercuribenzoic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA | CTD | PMID:27188386 | MIR22HG | Human | panobinostat | increases expression | EXP | | 6480464 | panobinostat results in increased expression of MIR22HG mRNA | CTD | PMID:26272509 | MIR22HG | Human | panobinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA | CTD | PMID:27188386 | MIR22HG | Human | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Mir22hg (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of MIR22HG mRNA | CTD | PMID:36331819 | MIR22HG | Human | phenobarbital | affects expression | ISO | Mir22hg (Mus musculus) | 6480464 | Phenobarbital affects the expression of MIR22HG mRNA | CTD | PMID:23091169 | MIR22HG | Human | phenylmercury acetate | increases expression | EXP | | 6480464 | Phenylmercuric Acetate results in increased expression of MIR22HG mRNA | CTD | PMID:26272509 | MIR22HG | Human | phenylmercury acetate | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA | CTD | PMID:27188386 | MIR22HG | Human | quercetin | increases expression | EXP | | 6480464 | Quercetin results in increased expression of MIR22HG mRNA | CTD | PMID:21632981 | MIR22HG | Human | rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of MIR22HG mRNA | CTD | PMID:29955902 | MIR22HG | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | MIR22HG | Human | silver atom | increases expression | EXP | | 6480464 | Silver results in increased expression of MIR22HG mRNA | CTD | PMID:26014281 | MIR22HG | Human | silver(0) | increases expression | EXP | | 6480464 | Silver results in increased expression of MIR22HG mRNA | CTD | PMID:26014281 | MIR22HG | Human | sodium arsenate | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of MIR22HG mRNA | CTD | PMID:32525701 | MIR22HG | Human | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of MIR22HG mRNA | CTD | PMID:28595984 and PMID:34032870 | MIR22HG | Human | testosterone | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of MIR22HG mRNA | CTD | PMID:21592394 | MIR22HG | Human | testosterone | increases expression | EXP | | 6480464 | Testosterone results in increased expression of MIR22HG mRNA | CTD | PMID:21592394 | MIR22HG | Human | tetrachloromethane | decreases expression | ISO | Mir22hg (Mus musculus) | 6480464 | Carbon Tetrachloride results in decreased expression of MIR22HG mRNA | CTD | PMID:31919559 | MIR22HG | Human | thapsigargin | increases expression | EXP | | 6480464 | Thapsigargin results in increased expression of MIR22HG mRNA | CTD | PMID:22378314 | MIR22HG | Human | titanium dioxide | decreases expression | ISO | Mir22hg (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of MIR22HG mRNA | CTD | PMID:29264374 | MIR22HG | Human | torcetrapib | increases expression | EXP | | 6480464 | torcetrapib results in increased expression of MIR22HG mRNA | CTD | PMID:23228038 | MIR22HG | Human | trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of MIR22HG mRNA | CTD | PMID:26272509 | MIR22HG | Human | trichostatin A | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA | CTD | PMID:27188386 | MIR22HG | Human | tris(2-butoxyethyl) phosphate | affects expression | EXP | | 6480464 | tris(2-butoxyethyl) phosphate affects the expression of MIR22HG mRNA | CTD | PMID:29024780 | MIR22HG | Human | trovafloxacin | increases expression | ISO | Mir22hg (Mus musculus) | 6480464 | trovafloxacin results in increased expression of MIR22HG mRNA | CTD | PMID:35537566 | MIR22HG | Human | tunicamycin | increases expression | EXP | | 6480464 | Tunicamycin results in increased expression of MIR22HG mRNA | CTD | PMID:22378314 | MIR22HG | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of MIR22HG mRNA | CTD | PMID:23179753 more ... | MIR22HG | Human | valproic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR22HG mRNA | CTD | PMID:27188386 | MIR22HG | Human | vorinostat | increases expression | EXP | | 6480464 | vorinostat results in increased expression of MIR22HG mRNA | CTD | PMID:26272509 | MIR22HG | Human | zinc atom | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of MIR22HG mRNA | CTD | PMID:18593933 | MIR22HG | Human | zinc(0) | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of MIR22HG mRNA | CTD | PMID:18593933 | MIR22HG | Human | zoledronic acid | decreases expression | EXP | | 6480464 | zoledronic acid results in decreased expression of MIR22HG mRNA | CTD | PMID:24714768 | |